Oral small molecule GLP-1 receptor agonist
Aleniglipron 45 mg tablet once daily
ALENIG_PO_45MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -6.06 (-16.05 to 5.54) | 0.64 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -7.81 (-13.61 to -0.05) | 0.62 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -7.40 (-13.72 to 0.54) | 0.51 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.46 (0.04 to 3.58) | 0.71 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.32 (0.60 to 9.36) | 0.44 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.86 (2.47 to 10.21) | 0.34 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.06 (2.42 to 23.63) | 0.31 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.03 (0.87 to 4.73) | 0.48 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.06 (1.15 to 8.68) | 0.33 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 4.92 (1.04 to 30.64) | 0.29 |